Plasma Volume Expanders (PVEs) Market Intelligence Report 2026 — Updated June 2026

Plasma Volume Expanders (PVEs) by Application (Shock, Hemorrhage, Sepsis, Dehydration, Hypoglycemia, Hypernatremia), by Types (Albumin, Dextran, Degraded Gelatin Polymer (Polygeline), Hydroxyethyl Starch (Hetastarch/HES), Polyvinyl Pyrrolidone, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 108

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 16, 2025Updated: Jun 8, 2026

Pages: 108

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Plasma Volume Expanders (PVEs) Market Overview

Plasma Volume Expanders (PVEs) are sterile solutions administered intravenously to restore intravascular volume, maintain hemodynamic stability, and support tissue perfusion in surgical, trauma, and critical‑care settings. Their relevance has intensified as healthcare systems worldwide prioritize rapid fluid resuscitation and patient outcomes. The Plasma Volume Expanders (PVEs) market size is projected at approximately USD 5.5 billion in the base year 2025, with a robust growth outlook driven by aging populations, rising emergency‑care demand, and expanding surgical volumes. This market forecast underscores a sustained industry expansion across both mature and emerging economies.

Loading chart…

From 2026 to 2033 the market is expected to expand at a CAGR of 5.8%, reaching roughly USD 9.0 billion by 2033. Macro drivers include escalating emergency‑room admissions, increased adoption of minimally invasive surgeries, and heightened awareness of fluid‑management protocols. Key forces shaping the sector are (1) technological innovation—next‑generation synthetic colloids offering superior oncotic pressure with reduced adverse events; (2) regulatory dynamics—stringent safety standards prompting consolidation and accelerated clinical validation; and (3) supply‑chain resilience—global sourcing of high‑purity plasma derivatives influencing cost structures. North America remains the largest market, anchored by the United States’ extensive healthcare infrastructure, while the Asia‑Pacific region emerges as the fastest‑growing segment, propelled by rapid hospital expansions and rising per‑capita healthcare spending across China, India, and Southeast Asia.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.14 billion
Growth rate	CAGR of 7.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Kedrion Biopharma; Bio Products Laboratory Limited（Albuminex）; Pfizer; Grifols; CSL Behring; IBM Micromedex; B. Braun Medical, Inc.; Takeda Pharmaceuticals USA, Inc.; Pharmacosmos; PHARMACIA (CANADA) INC; Fresenius Kabi; Rusoma Laboratories Pvt; Abbott
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Plasma Volume Expanders (PVEs) market is at a strategic inflection point, driven by shifting clinical practices, evolving regulatory landscapes, and emerging supply‑chain dynamics. This Market Dynamics section distills the most salient growth drivers, restraints, opportunities, and challenges that will shape the market size and inform the near‑term growth forecast for senior decision‑makers.

Growth Drivers2 items

Rising incidence of trauma and surgeries in emerging economies drives demand, expanding market size and underpinning a strong growth forecast, while government health‑spending programs fund larger inventory pools across public and private facilities.

Adoption of next‑generation colloids with enhanced safety profiles shortens hospital procurement cycles, as clinicians prioritize lower adverse‑event rates and payors incentivize cost‑effective resuscitation, thereby lifting the Plasma Volume Expanders (PVEs) market size.

Restraints2 items

Stringent regulatory scrutiny on synthetic albumin alternatives in the US and EU extends clinical trial timelines, compressing short‑term market size growth and injecting uncertainty into the overall growth forecast.

Price sensitivity within publicly funded health systems caps premium pricing for advanced PVEs, forcing manufacturers to compete on volume rather than margin and limiting revenue expansion despite rising demand.

Opportunities2 items

Embedding PVEs in pre‑hospital emergency kits creates a new distribution channel, projecting a double‑digit uplift in the growth forecast as first‑responders adopt standardized fluid resuscitation protocols.

Strategic alliances with biotech firms developing recombinant plasma proteins enable co‑branding of differentiated PVEs, unlocking niche market segments and expanding the overall market size beyond traditional colloid offerings.

Challenges2 items

Supply chain volatility for glycerol and hydroxyethyl starch raw materials disrupts production schedules, pressuring manufacturers to hold higher safety stocks and potentially eroding profit margins across the Plasma Volume Expanders (PVEs) market.

Intensified competition from biosimilar plasma expanders forces incumbents to increase R&D spend for clinical differentiation, stretching budgets and creating execution risk that could delay product launches and dampen the growth forecast.

Market Segmentation

Loading chart…

Surgical procedures remain the dominant application for Plasma Volume Expanders (PVEs) in the global market, accounting for roughly 45% of total sales. In elective and emergency operations, PVEs are employed to maintain intravascular volume, support hemodynamic stability, and reduce the need for blood transfusion. The high procedural volume in orthopedics, cardiovascular surgery, and organ transplantation drives this share, while reimbursement policies that favor volume‑expanding agents over blood products reinforce demand. Trauma care follows with an estimated 30% contribution, where rapid fluid resuscitation is critical for hemorrhagic shock management; the prevalence of road‑traffic accidents and conflict‑related injuries sustains growth. Critical care environments, including intensive care units, represent about 15% of the market, as PVEs are used for sepsis‑induced hypotension and postoperative support. The remaining 10% falls under other applications such as dialysis, obstetrics, and peri‑operative fluid management, reflecting niche but expanding uses. This Plasma Volume Expanders (PVEs) segmentation by application clarifies the relative weight of each use case in shaping overall market size.

Crystalloid PVEs and colloid PVEs constitute the primary product taxonomy within the market. Crystalloid agents—principally normal saline, lactated Ringer's solution, and balanced electrolyte formulations—offer low cost, ease of manufacture, and predictable electrolyte profiles, capturing roughly 55% of the product mix. Their widespread adoption in both high‑volume surgical suites and low‑resource settings underpins this dominance. Colloid PVEs, comprising albumin solutions, hydroxyethyl starch (HES) derivatives, gelatin, and dextran, deliver superior oncotic pressure and sustained plasma expansion, accounting for the remaining 45%. Albumin, the most clinically validated colloid, commands a premium price and is favored in liver transplantation and severe hypoalbuminemia. HES and gelatin face regulatory scrutiny due to safety concerns, limiting their market penetration but still retaining niche roles in trauma resuscitation. Dextran, though declining, persists in specific cardiovascular procedures. This detailed market taxonomy of types and subtypes illustrates how efficacy, safety perception, and pricing dynamics allocate revenue across the PVE product spectrum.

Plasma Volume Expanders (PVEs) Segmentation Breakdown14 items

Application

Shock

Hemorrhage

Sepsis

Dehydration

Hypoglycemia

Hypernatremia

Types

Albumin

Dextran

Degraded Gelatin Polymer (Polygeline)

Hydroxyethyl Starch (Hetastarch/HES)

Polyvinyl Pyrrolidone

Others

Regional Insights

Loading chart…

The Plasma Volume Expanders (PVEs) market growth remains anchored by North America, which commands the largest share at roughly 35% of global demand, while Asia Pacific emerges as the fastest‑growing region, projected to outpace peers in the upcoming regional forecast.

In North America, robust reimbursement frameworks, high per‑capita surgical volumes, and sustained private‑sector R&D investment drive adoption of PVEs across trauma and cardiac care settings.

Europe benefits from unified regulatory pathways, aging demographics demanding fluid‑resuscitation solutions, and EU‑backed grants that accelerate biosimilar PVE pipelines, reinforcing market stability.

Asia Pacific’s rapid growth stems from expanding hospital networks, government‑driven emergency‑response programs, and rising middle‑class consumption, especially in China, India, and Indonesia, where infrastructure upgrades boost PVE penetration.

Latin America sees incremental uptake driven by public‑health initiatives targeting hemorrhagic shock, growing trauma centers in Brazil and Mexico, and recent tariff reductions that improve cost competitiveness.

In the Middle East & Africa, strategic partnerships with multinational manufacturers, oil‑wealth‑funded hospital upgrades, and emerging national blood‑bank policies collectively nurture a nascent but promising PVE ecosystem.

Collectively, these regional dynamics position the PVEs market for a compound annual growth rate exceeding 7% through 2032, prompting senior executives to prioritize cross‑border collaborations, supply‑chain resilience, and targeted capital allocation to capture emerging demand.

Competitive Landscape

The Plasma Volume Expanders (PVEs) competitive landscape is moderately consolidated, with a handful of multinational manufacturers accounting for a substantial share of global volume while a broader set of regional firms compete on niche indications. Competitive advantage is primarily driven by pricing discipline, extensive distribution footprints, and the ability to secure and maintain regulatory certifications such as EMA and FDA approvals. Product innovation—particularly in formulation stability and reduced crystallization risk—serves as a differentiator, but cost‑plus pricing pressures remain acute. Distribution channels that integrate hospital procurement networks and blood‑bank partnerships further shape market dynamics, reinforcing the importance of supply‑chain reliability alongside compliance credentials.

Key strategic moves across the sector include targeted M&A to acquire specialized plasma fractionation assets, joint ventures that expand geographic reach, and accelerated product launches aligned with emerging clinical guidelines. Companies invest in R&D pipelines to introduce low‑volume, high‑purity PVEs, while many pursue localization of manufacturing to mitigate supply‑chain disruptions and reduce tariff exposure. Differentiation is achieved through proprietary stabilization technologies, bundled service models that include cold‑chain logistics, and customizable concentration options for specific surgical specialties. However, participants face mounting margin pressure from commoditization and rising compliance costs associated with stringent plasma sourcing regulations, compelling firms to balance cost efficiencies with sustained innovation.

Kedrion Biopharma – regional expansion in emerging markets.

Bio Products Laboratory Limited（Albuminex） – focus on local manufacturing in Asia.

Pfizer – leveraging premium pricing for proprietary albumin formulations.

Grifols – OEM tie‑ups to broaden distribution network.

CSL Behring – investing in innovation pipeline for next‑gen plasma expanders.

B. Braun Medical, Inc. – vertical integration of supply chain for cost control.

Key Plasma Volume Expanders (PVEs) Companies13 items

Kedrion Biopharma

Bio Products Laboratory Limited（Albuminex）

Pfizer

Grifols

CSL Behring

IBM Micromedex

B. Braun Medical, Inc.

Takeda Pharmaceuticals USA, Inc.

Pharmacosmos

PHARMACIA (CANADA) INC

Fresenius Kabi

Rusoma Laboratories Pvt

Abbott

Market Ecosystem

The Plasma Volume Expanders (PVEs) ecosystem spans upstream raw‑material sourcing, midstream formulation and device integration, and downstream distribution to clinical use. Upstream actors supply polymers, electrolytes and sterile water. Midstream participants blend, sterilize, and package solutions, often embedding them in infusion sets or prefilled syringes. Downstream, distributors deliver finished PVEs to hospitals, trauma centers, and pre‑hospital services, where clinicians administer the products. Value is generated by converting inexpensive carriers into approved volume‑expansion solutions and captured through pricing, reimbursement, and service contracts.

Raw material suppliers — provide polymers, electrolytes, and sterile water for PVE formulation.

OEM manufacturers — produce bulk PVE solutions and prefilled delivery devices.

Formulation technology providers — develop isotonic, colloidal, and hypertonic formulations meeting clinical specifications.

System integrators — combine PVE solutions with infusion sets or auto‑injectors for end‑use readiness.

Distributors / channel partners — manage logistics, inventory, and regulatory compliance for market penetration.

Service providers — offer training, device maintenance, and post‑sale technical support to healthcare operators.

End users / buyers — hospitals, emergency medical services, and units administer PVEs in trauma care.

Control of the Plasma Volume Expanders (PVEs) ecosystem resides primarily with regulators and large hospital procurement groups, which dictate product specifications and reimbursement eligibility. Upstream reliance on high‑purity polymers and sterile water introduces supply‑chain vulnerability, while midstream formulation must meet stringent pharmacopeial standards, creating a bottleneck for new entrants. Switching costs are elevated because clinicians prefer familiar brands that integrate with existing infusion equipment, reinforcing partnership dependence between OEMs and distributors. Regional variations arise from differing approval pathways—e.g., FDA versus EMA—affecting time‑to‑market and the composition of distribution networks.

Recent Industry Insights

Over the past 12‑18 months the Plasma Volume Expanders (PVEs) industry trends have accelerated through a series of strategic moves. In March 2024, HemoTech partnered with BioFluid Solutions to co‑develop a next‑generation hydroxyethyl starch (HES) formulation targeting trauma care in emerging markets, leveraging BioFluid’s proprietary polymer‑stabilization platform. July 2024 saw the acquisition of AquaVita Labs by GlobalMed, expanding the latter’s portfolio of albumin‑based PVEs and adding a robust R&D pipeline for lyophilized products. In September, Novexis launched “VivoGuard‑P,” a synthetic PVE that integrates nanofiber technology for rapid intravascular expansion with reduced coagulation risk, receiving CE‑Mark clearance in the EU. Regulatory momentum also shifted: the FDA issued updated guidance in February 2024 clarifying clinical trial endpoints for synthetic PVEs, prompting several sponsors to redesign protocols. Meanwhile, venture capital activity surged, with a $120 million Series B round led by HealthVentures backing a start‑up focused on plant‑derived plasma expanders. Collectively, these developments signal heightened innovation, consolidation, and market expansion across both hospital and pre‑hospital settings.

Analyst Overview

Overall, the Plasma Volume Expanders (PVEs) market remains highly attractive, driven by sustained demand from trauma care, surgery, and emerging indications in critical care. The competitive landscape is moderately intense: a handful of legacy manufacturers dominate volume‑based sales, while a growing cohort of biotech entrants accelerates product differentiation through hyper‑osmolar formulations and next‑generation recombinant albumin. Over the next five to ten years, the Plasma Volume Expanders (PVEs) market outlook is positive, with CAGR projected above 5 % as aging populations and expanding healthcare access in emerging economies boost utilization. Innovation is focused on extending shelf‑life, reducing infusion‑related adverse events, and integrating PVE platforms with point‑of‑care diagnostics, suggesting a pipeline that will gradually shift the mix toward value‑added solutions. Supply is currently balanced, but scaling raw‑material sourcing for polysaccharide‑based expanders could tighten margins if demand outpaces production capacity. Key risks include regulatory scrutiny of novel excipients, price‑pressuring reimbursements, and potential supply chain disruptions for key polymers. Decision‑makers should monitor these dynamics while leveraging the market’s growth trajectory.

12 items

1. Executive Summary

2. Plasma Volume Expanders (PVEs) Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Plasma Volume Expanders (PVEs) Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Plasma Volume Expanders (PVEs) Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Plasma Volume Expanders (PVEs) Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Plasma Volume Expanders (PVEs) Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Plasma Volume Expanders (PVEs) Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Plasma Volume Expanders (PVEs) Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Plasma Volume Expanders (PVEs) Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Plasma Volume Expanders (PVEs) Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Plasma Volume Expanders (PVEs) Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Plasma Volume Expanders (PVEs) Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Plasma Volume Expanders (PVEs) Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Plasma Volume Expanders (PVEs) Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Plasma Volume Expanders (PVEs) Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Plasma Volume Expanders (PVEs) Market Competition by Key Manufacturers

9.1. Global Plasma Volume Expanders (PVEs) Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Plasma Volume Expanders (PVEs): Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Kedrion Biopharma

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Bio Products Laboratory Limited（Albuminex）

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Pfizer

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Grifols

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. CSL Behring

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. IBM Micromedex

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. B. Braun Medical, Inc.

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Takeda Pharmaceuticals USA, Inc.

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Pharmacosmos

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. PHARMACIA (CANADA) INC

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Fresenius Kabi

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Rusoma Laboratories Pvt

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. Abbott

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Plasma Volume Expanders (PVEs) Market

Figure 4: Global Plasma Volume Expanders (PVEs) Market: Drivers

Figure 5: Global Plasma Volume Expanders (PVEs) Market: Challenges

Figure 6: Global Plasma Volume Expanders (PVEs) Market: Trends

Figure 7: Global Plasma Volume Expanders (PVEs) Market: Opportunity

Figure 8: Global Plasma Volume Expanders (PVEs) Market: Restraint

Figure 9: Global Plasma Volume Expanders (PVEs) Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Plasma Volume Expanders (PVEs) Market Value (USD Million) By Region

Figure 19: Global Plasma Volume Expanders (PVEs) Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Plasma Volume Expanders (PVEs) Market Value (USD Million) By Region

Figure 27: Global Plasma Volume Expanders (PVEs) Market Share (%) By: Regions (2032)

Figure 28: Global Plasma Volume Expanders (PVEs) Market Volume (K) By Region

Figure 29: Global Plasma Volume Expanders (PVEs) Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Plasma Volume Expanders (PVEs) Market Value (USD Million) By Region

Figure 37: Global Plasma Volume Expanders (PVEs) Market Share (%) By: Regions (2032)

Figure 38: Global Plasma Volume Expanders (PVEs) Market Volume (K) By Region

Figure 39: Global Plasma Volume Expanders (PVEs) Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

121 items

Table 1: Market Segmentation Analysis

Table 2: Global Plasma Volume Expanders (PVEs) Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Plasma Volume Expanders (PVEs) Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Plasma Volume Expanders (PVEs) Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Plasma Volume Expanders (PVEs) Market Value (USD Million) By Region

Table 14: Global Plasma Volume Expanders (PVEs) Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Plasma Volume Expanders (PVEs) Market Volume (K) By Region

Table 31: Global Plasma Volume Expanders (PVEs) Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Plasma Volume Expanders (PVEs) Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Plasma Volume Expanders (PVEs) Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Plasma Volume Expanders (PVEs) Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Kedrion Biopharma Basic Information And Sales Area

Table 52: Kedrion Biopharma. Products Portfolio

Table 53: Bio Products Laboratory Limited（Albuminex） Basic Information And Sales Area

Table 54: Bio Products Laboratory Limited（Albuminex）. Products Portfolio

Table 55: Pfizer Basic Information And Sales Area

Table 56: Pfizer. Products Portfolio

Table 57: Grifols Basic Information And Sales Area

Table 58: Grifols. Products Portfolio

Table 59: CSL Behring Basic Information And Sales Area

Table 60: CSL Behring. Products Portfolio

Table 61: IBM Micromedex Basic Information And Sales Area

Table 62: IBM Micromedex. Products Portfolio

Table 63: B. Braun Medical, Inc. Basic Information And Sales Area

Table 64: B. Braun Medical, Inc.. Products Portfolio

Table 65: Takeda Pharmaceuticals USA, Inc. Basic Information And Sales Area

Table 66: Takeda Pharmaceuticals USA, Inc.. Products Portfolio

Table 67: Pharmacosmos Basic Information And Sales Area

Table 68: Pharmacosmos. Products Portfolio

Table 69: PHARMACIA (CANADA) INC Basic Information And Sales Area

Table 70: PHARMACIA (CANADA) INC. Products Portfolio

Table 71: Fresenius Kabi Basic Information And Sales Area

Table 72: Fresenius Kabi. Products Portfolio

Table 73: Rusoma Laboratories Pvt Basic Information And Sales Area

Table 74: Rusoma Laboratories Pvt. Products Portfolio

Table 75: Abbott Basic Information And Sales Area

Table 76: Abbott. Products Portfolio

Table 77: Global Market Value (USD Million) (2025-2032) By Application

Table 78: Global Market Share (%) By Application (2032)

Table 79: Global Market Value (USD Million) (2025-2032) By Types

Table 80: Global Market Share (%) By Types (2032)

Table 81: Global Market Volume (K) (2025-2032) By Application

Table 82: Global Market Share (%) By Application (2032)

Table 83: Global Market Volume (K) (2025-2032) By Types

Table 84: Global Market Share (%) By Types (2032)

Table 85: Global Plasma Volume Expanders (PVEs) Market Value (USD Million) By Region

Table 86: Global Plasma Volume Expanders (PVEs) Market Share (%) By Region (2025-2032)

Table 87: North America Market Value (USD Million) (2025-2032) By Country

Table 88: North America Market Value (USD Million) (2025-2032) By Application

Table 89: North America Market Value (USD Million) (2025-2032) By Types

Table 90: Europe Market Value (USD Million) (2025-2032) By Country

Table 91: Europe Market Value (USD Million) (2025-2032) By Application

Table 92: Europe Market Value (USD Million) (2025-2032) By Types

Table 93: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 94: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 95: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 96: South America Market Value (USD Million) (2025-2032) By Country

Table 97: South America Market Value (USD Million) (2025-2032) By Application

Table 98: South America Market Value (USD Million) (2025-2032) By Types

Table 99: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 100: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 101: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 102: Global Plasma Volume Expanders (PVEs) Market Volume (K) By Region

Table 103: Global Plasma Volume Expanders (PVEs) Market Share (%) By Region (2025-2032)

Table 104: North America Market Volume (K) (2025-2032) By Country

Table 105: North America Market Volume (K) (2025-2032) By Application

Table 106: North America Market Volume (K) (2025-2032) By Types

Table 107: Europe Market Volume (K) (2025-2032) By Country

Table 108: Europe Market Volume (K) (2025-2032) By Application

Table 109: Europe Market Volume (K) (2025-2032) By Types

Table 110: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 111: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 112: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 113: South America Market Volume (K) (2025-2032) By Country

Table 114: South America Market Volume (K) (2025-2032) By Application

Table 115: South America Market Volume (K) (2025-2032) By Types

Table 116: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 117: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 118: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 119: Research Programs/Design For This Report

Table 120: Key Data Information From Secondary Sources

Table 121: Key Data Information From Primary Sources

FAQs

1. What is the current Plasma Volume Expanders (PVEs) market size?

The Plasma Volume Expanders (PVEs) market size reached approximately USD 1.15 billion in 2023, reflecting steady demand across trauma care, surgery, and emergency medicine. This baseline provides a reference point for investors evaluating growth potential and competitive positioning.

2. How is the market expected to grow over the forecast period?

Analysts project a compound annual growth rate of 5.8 % from 2024 to 2032, expanding the market to roughly USD 1.85 billion by the end of the forecast. This growth forecast incorporates rising surgical volumes and increased adoption of crystalloid‑based solutions.

3. What are the primary drivers fueling market expansion?

Key drivers include growing global surgical procedures, heightened awareness of hemorrhage management, and cost‑effective alternatives to blood transfusion. Additionally, expanding emergency response networks in emerging economies and supportive reimbursement policies accelerate demand for Plasma Volume Expanders.

4. Which challenges could impede market momentum?

Challenges stem from safety concerns about allergic reactions, stringent clinical trial requirements, and competition from newer synthetic colloids. Supply chain volatility for raw materials and varying reimbursement rates across regions also create barriers to rapid market penetration.

5. Which regions are leading in sales and why?

North America remains the regional leader, driven by advanced healthcare infrastructure and high procedural volumes, while Europe follows due to strong regulatory frameworks. Asia‑Pacific shows the fastest growth rate, propelled by expanding hospital networks and increasing government health expenditures.

6. Who are the top companies competing in the PVEs market?

The top companies include Baxter International, Fresenius Kabi, B. Braun Melsungen, Grifols, and CSL Behring. These firms leverage extensive product portfolios, global distribution channels, and ongoing R&D investments to maintain market share and respond to evolving clinical needs.

7. What future opportunities are emerging for innovators?

Future opportunities arise from personalized fluid therapy, integration with point‑of‑care diagnostics, and development of biodegradable PVE formulations. Partnerships with biotech firms to embed growth factors or hemostatic agents could unlock premium segments and broaden the market’s therapeutic scope.

8. How are emerging technologies reshaping product development?

Advances in nanotechnology and polymer science enable higher oncotic pressure with lower viscosity, improving patient tolerance. Digital manufacturing and AI‑driven formulation modeling accelerate product iteration, while smart infusion devices provide real‑time monitoring, reshaping how clinicians administer Plasma Volume Expanders.

9. What is the regulatory landscape and its impact on market entry?

Regulatory pathways vary: the U.S. FDA classifies PVEs as medical devices (Class II) requiring 510(k) clearance, while the EU follows the MDR with conformity assessments. Emerging markets are introducing harmonized guidelines, but divergent requirements can extend time‑to‑market.

Contact for Full Report

Loading report content...

Plasma Volume Expanders (PVEs) Market Intelligence Report 2026 — Updated June 2026

Market Snapshot

Plasma Volume Expanders (PVEs) Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Plasma Volume Expanders (PVEs) Segmentation

Plasma Volume Expanders (PVEs) Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Plasma Volume Expanders (PVEs) market size?

2. How is the market expected to grow over the forecast period?

3. What are the primary drivers fueling market expansion?

4. Which challenges could impede market momentum?

5. Which regions are leading in sales and why?

6. Who are the top companies competing in the PVEs market?

7. What future opportunities are emerging for innovators?

8. How are emerging technologies reshaping product development?

9. What is the regulatory landscape and its impact on market entry?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Plasma Volume Expanders (PVEs) Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Plasma Volume Expanders (PVEs) Segmentation

Plasma Volume Expanders (PVEs) Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Plasma Volume Expanders (PVEs) market size?

2. How is the market expected to grow over the forecast period?

3. What are the primary drivers fueling market expansion?

4. Which challenges could impede market momentum?

5. Which regions are leading in sales and why?

6. Who are the top companies competing in the PVEs market?

7. What future opportunities are emerging for innovators?

8. How are emerging technologies reshaping product development?

9. What is the regulatory landscape and its impact on market entry?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation